NAS:BMRN (USA) Also trade in: Austria Germany UK

Biomarin Pharmaceutical Inc

$ 83.3 0.35 (0.42%)
On watch
Volume: 142,154 Avg Vol (1m): 1,435,329
Market Cap $: 14.85 Bil Enterprise Value $: 14.78 Bil
P/E (TTM): 0.00 P/B: 5.04
Earnings Power Value -12.37
Net Current Asset Value 2.35
Tangible Book 12.64
Projected FCF -7.72
Median P/S Value 99.99
Graham Number 0
Peter Lynch Value 0
DCF (FCF Based) 0
DCF (Earnings Based) 0
1Y (-%)

Financial Strength : 6.4/10

GuruFocus Financial Strength Rank measures how strong a company's financial situation is . It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
Current vs industry vs history
Cash-to-Debt 1.07
Cash-To-Debt range over the past 10 years
Min: 0.12, Med: 1.14, Max: 10000
Current: 1.07
0.12
10000
Equity-to-Asset 0.66
Equity-to-Asset range over the past 10 years
Min: -0.66, Med: 0.62, Max: 0.97
Current: 0.66
-0.66
0.97
Debt-to-Equity 0.28
Debt-to-Equity range over the past 10 years
Min: -3.98, Med: 0.41, Max: 19.12
Current: 0.28
-3.98
19.12
Debt-to-EBITDA -58.91
Debt-to-EBITDA range over the past 10 years
Min: -2025.17, Med: -5.09, Max: 22.12
Current: -58.91
-2025.17
22.12
Piotroski F-Score 5
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 6.04
DISTRESS
GREY
SAFE
Beneish M-Score -2.34
Not Manipulator
Manipulator
WACC vs ROIC %
ROIC -4.17%
WACC 9.28%

Profitability & Growth : 5/10

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
Current vs industry vs history
Operating Margin % -12.06
Operating Margin range over the past 10 years
Min: -31.63, Med: -14.97, Max: 5.06
Current: -12.06
-31.63
5.06
Net Margin % -5.90
Net Margin range over the past 10 years
Min: -56.43, Med: -15.04, Max: 54.7
Current: -5.9
-56.43
54.7
ROE % -3.08
ROE range over the past 10 years
Min: -24.39, Med: -7.99, Max: 39.6
Current: -3.08
-24.39
39.6
ROA % -1.97
ROA range over the past 10 years
Min: -16.26, Med: -4.87, Max: 18.88
Current: -1.97
-16.26
18.88
ROC (Joel Greenblatt) % -7.74
ROC (Joel Greenblatt) range over the past 10 years
Min: -89.83, Med: -12.24, Max: 5.59
Current: -7.74
-89.83
5.59
3-Year Total Revenue Growth Rate 18.80
3-Year Revenue Growth Rate range over the past 10 years
Min: -10.4, Med: 13.75, Max: 97.3
Current: 14.8
-10.4
97.3
3-Year Total EBITDA Growth Rate 54.20
3-Year EBITDA Growth Rate range over the past 10 years
Min: 0, Med: -46.2, Max: 55.9
Current: 55.9
0
55.9
3-Year EPS w/o NRI Growth Rate 25.60
3-Year EPS w/o NRI Growth Rate range over the past 10 years
Min: 0, Med: -25.9, Max: 62
Current: 25.6
0
62

» BMRN's 30-Y Financials

Financials (Next Earnings Date: 2019-08-02)

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with NAS:BMRN

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Biotechnology » Biotechnology    NAICS : 325412    SIC : 2834
Compare XBRU:UCB OCSE:NZYM B HKSE:01177 NAS:INCY XKRX:207940 OCSE:GEN NAS:SRPT NAS:SGEN HKSE:02269 NAS:ARRY NAS:SAGE NAS:IONS SZSE:000661 NAS:JAZZ XKRX:068270 NAS:TECH NAS:ALNY NAS:NBIX HKSE:06160 NAS:LOXO
Traded in other countries BM8.Germany 0HNC.UK
Address 770 Lindaro Street, San Rafael, CA, USA, 94901
BioMarin's focus is on rare-disease therapies. Genzyme (now part of Sanofi) markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme and Vimizim independently. BioMarin markets Kuvan--to treat the rare metabolic disorder PKU--in the U.S., and recently reacquired international rights for Kuvan and PKU drug candidate pegvaliase from Merck KGaA. BioMarin expanded its pipeline with acquisitions in 2010 (LEAD Therapeutics and Zystor) and 2015 (Prosensa).

Ratios

Current vs industry vs history
Forward PE Ratio 107.53
N/A
PB Ratio 5.04
PB Ratio range over the past 10 years
Min: 3.67, Med: 5.79, Max: 12.14
Current: 5.04
3.67
12.14
PS Ratio 9.71
PS Ratio range over the past 10 years
Min: 3.38, Med: 11.71, Max: 27.08
Current: 9.71
3.38
27.08
Price-to-Operating-Cash-Flow 1927.90
Price-to-Operating-Cash-Flow range over the past 10 years
Min: 19.75, Med: 238.57, Max: 43300
Current: 1927.9
19.75
43300
EV-to-EBIT -136.10
EV-to-EBIT range over the past 10 years
Min: -17265.1, Med: -64.2, Max: 5182.8
Current: -136.1
-17265.1
5182.8
EV-to-EBITDA -1043.40
EV-to-EBITDA range over the past 10 years
Min: -26007, Med: -78.8, Max: 1043.5
Current: -1043.4
-26007
1043.5
EV-to-Revenue 9.74
EV-to-Revenue range over the past 10 years
Min: 3.3, Med: 11.6, Max: 27.8
Current: 9.74
3.3
27.8
Current Ratio 3.83
Current Ratio range over the past 10 years
Min: 0.9, Med: 6, Max: 18.94
Current: 3.83
0.9
18.94
Quick Ratio 2.76
Quick Ratio range over the past 10 years
Min: 0.82, Med: 5.06, Max: 18.77
Current: 2.76
0.82
18.77
Days Inventory 570.10
Days Inventory range over the past 10 years
Min: 420.4, Med: 543.07, Max: 627.16
Current: 570.1
420.4
627.16
Days Sales Outstanding 94.57
Days Sales Outstanding range over the past 10 years
Min: 67.66, Med: 78.96, Max: 94.57
Current: 94.57
67.66
94.57
Days Payable 254.26
Days Payable range over the past 10 years
Min: 25.74, Med: 259.21, Max: 430.52
Current: 254.26
25.74
430.52

Dividend & Buy Back

Current vs industry vs history
3-Year Share Buyback Rate -3.10
3-Year Share Buyback Rate range over the past 10 years
Min: -32.6, Med: -8.85, Max: -3.1
Current: -3.1
-32.6
-3.1

Valuation & Return

Current vs industry vs history
Price-to-Tangible-Book 6.56
Price-to-Tangible-Book range over the past 10 years
Min: 2.13, Med: 7.53, Max: 116.7
Current: 6.56
2.13
116.7
Price-to-Median-PS-Value 0.83
Price-to-Median-PS-Value range over the past 10 years
Min: 0.35, Med: 1.42, Max: 12.91
Current: 0.83
0.35
12.91
Earnings Yield (Joel Greenblatt) % -0.73
Earnings Yield (Greenblatt) range over the past 10 years
Min: -5.7, Med: -0.8, Max: 3.7
Current: -0.73
-5.7
3.7

More Statistics

Revenue (TTM) (Mil) $ 1,518.51
EPS (TTM) $ -0.51
Beta 1.21
Volatility % 24.47
52-Week Range $ 79.13 - 106.74
Shares Outstanding (Mil) 178.25

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 5
Positive ROA N
Positive CFROA Y
Higher ROA yoy Y
CFROA > ROA Y
Lower Leverage yoy Y
Higher Current Ratio yoy Y
Less Shares Outstanding yoy N
Higher Gross Margin yoy N
Higher Asset Turnover yoy N